Universal Ibogaine Inc
- LAST PRICE0.0100
- TODAY'S CHANGE (%)-0.0050 (-33.3333%)
- Bid / Lots0.0100/ 12
- Ask / Lots0.0150/ 721
- Open / Previous Close0.0100 / 0.0150
- Day Range
- 52 Week Range
- Volume139,000
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IBO |
|---|---|---|
| 09:32 ET | 20000 | 0.01 |
| 10:38 ET | 100000 | 0.01 |
| 01:00 ET | 19000 | 0.01 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Universal Ibogaine Inc | 4.6M | -1.5x | --- |
Sproutly Canada Inc | 5.5M | -0.5x | --- |
Element Lifestyle Retirement Inc | 1.1M | 6.6x | --- |
Revitalist Lifestyle and Wellness Ltd | 2.8M | -0.1x | --- |
AJA Health And Wellness Inc | 2.6M | 0.0x | --- |
Braxia Scientific Corp | 842.9K | -0.1x | --- |
Company Information
Universal Ibogaine Inc. is a Canada-based life sciences company. The Company is transforming addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorders. The Company is engaged in developing a holistic addiction treatment protocol at its Kelburn Recovery Center (located near Winnipeg, Manitoba), which paired with the planned ibogaine detox protocol, is intended to treat addiction and improve the lives of individuals and families affected by addiction. Ibogaine is a naturally occurring molecule derived from the root bark of the iboga tree and other plants. It is a potent and serious medical psychedelic which has addiction interrupting properties. Ibogaine targets multiple receptors across multiple sites in the brain and metabolizes into noribogaine, a serotonin re-uptake inhibitor that remains in the body for 1-4 months, associated with elimination of addictive cravings.
Contact Information
- Headquarters
- (c/o Suite 600 - 815 8th Avenue SWCALGARY, AB, Canada T2P 3P2
- Phone
- 403-870-1841
- Fax
- 403-870-1841
Executives
- Chief Executive Officer
- Nicholas Karos
- Chief Financial Officer
- Greg Leavens
- Chief Clinics Officer
- Ian Rabb
- Independent Director
- Ken Cranwill
- Independent Director
- James Duncan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.6M |
|---|---|
Revenue (TTM) | $2.3M |
Shares Outstanding | 304.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.01 |
Book Value | $0.01 |
P/E Ratio | -1.5x |
Price/Sales (TTM) | 2.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -49.87% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
